Development of the Weight-Tiered Q3W Regimen of Amivantamab in Combination With Carboplatin-Pemetrexed in EGFR-Mutated Non-Small Cell Lung Cancer.

Yuan D, Bishop CJ, Mehta J, Zhou W, Zhang L, Zhou J, Venkatasubramanian R, Yu A, Agrawal T, Shah S, Baig M, Bauml JM, Kambuj P, Ojeda LC, Clemens PL, Haddish-Berhane N, Su Y, Samtani M

Open source

DOI: 10.1002/psp4.70263
Published: 2026 Jun
Container: CPT: pharmacometrics & systems pharmacology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/psp4.70263,
  title = {Development of the Weight-Tiered Q3W Regimen of Amivantamab in Combination With Carboplatin-Pemetrexed in EGFR-Mutated Non-Small Cell Lung Cancer.},
  author = {Yuan D and Bishop CJ and Mehta J and Zhou W and Zhang L and Zhou J and Venkatasubramanian R and Yu A and Agrawal T and Shah S and Baig M and Bauml JM and Kambuj P and Ojeda LC and Clemens PL and Haddish-Berhane N and Su Y and Samtani M},
  year = {2026},
  journal = {CPT: pharmacometrics \& systems pharmacology},
  doi = {10.1002/psp4.70263},
  url = {https://doi.org/10.1002/psp4.70263}
}

RIS

TY  - JOUR
TI  - Development of the Weight-Tiered Q3W Regimen of Amivantamab in Combination With Carboplatin-Pemetrexed in EGFR-Mutated Non-Small Cell Lung Cancer.
AU  - Yuan D
AU  - Bishop CJ
AU  - Mehta J
AU  - Zhou W
AU  - Zhang L
AU  - Zhou J
AU  - Venkatasubramanian R
AU  - Yu A
AU  - Agrawal T
AU  - Shah S
AU  - Baig M
AU  - Bauml JM
AU  - Kambuj P
AU  - Ojeda LC
AU  - Clemens PL
AU  - Haddish-Berhane N
AU  - Su Y
AU  - Samtani M
PY  - 2026
JO  - CPT: pharmacometrics & systems pharmacology
DO  - 10.1002/psp4.70263
UR  - https://doi.org/10.1002/psp4.70263
ER  -

APA

D, Y., CJ, B., J, M., W, Z., L, Z., J, Z., R, V., A, Y., T, A., S, S., M, B., JM, B., P, K., LC, O., PL, C., N, H., Y, S., & M, S. (2026). Development of the Weight-Tiered Q3W Regimen of Amivantamab in Combination With Carboplatin-Pemetrexed in EGFR-Mutated Non-Small Cell Lung Cancer.. CPT: pharmacometrics & systems pharmacology. https://doi.org/10.1002/psp4.70263

Source records

pubmed · retrieved 2026-09-24T21:47:27.127Z